sb 202190 has been researched along with Lymphoma, B-Cell in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Lymphoma, B-Cell: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yi, AK | 1 |
| Krieg, AM | 1 |
1 other study available for sb 202190 and Lymphoma, B-Cell
| Article | Year |
|---|---|
Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA.
Topics: Activating Transcription Factor 2; Adjuvants, Immunologic; Animals; Calcium-Calmodulin-Dependent Pro | 1998 |